Temozolomide a good option for late adjuvant therapy in melanoma patients
Use of a single-agent temozolomide appears to be an effective alternative to late adjuvant therapy in patients with melanoma if novel treatments, such as targeting and immune therapies, are not available, suggests a recent study.
